Zusammenfassung
Das Peniskarzinom ist glücklicherweise eine relativ seltene Erkrankung in Mitteleuropa, denn fortgeschrittene Tumorstadien sind nicht heilbar. Aber diese Seltenheit bedingt auch Nachteile für die Betroffenen: Daten größerer Serien als Evidenzgrundlage sind selten, Leitlinien in ihren Formulierungen oft entsprechend vage und Forschungsmittel für Therapiestudien rar. Das Peniskarzinom ist eine „orphan disease“. Trotz dieser nachteiligen Besonderheiten haben insbesondere auch Forschungen zu den molekularbiologischen Grundlagen des Peniskarzinoms in den letzten Jahren einige Fortschritte ermöglicht. Dieser Artikel gibt eine aktuelle Übersicht zu allen relevanten Aspekten dieser Erkrankung.
Abstract
Penile carcinoma is fortunately a relatively rare disease in central Europe because advanced tumor stages are incurable. However, this rarity results in disadvantages for those affected because data from large series as an evidence basis are rare, the formulation of guidelines is often correspondingly vague and research funding for therapy studies is limited. Penile carcinoma is an orphan disease. Despite these disadvantageous characteristics research on the molecular biological basis of penile carcinoma has made some progress in recent years. This article gives a current review of all relevant aspects of this disease.
Literatur
Parkin DM, Whelan SL, Ferlay J et al (eds) (2002) Cancer Incidence in Five Continents. IARC Scientific Publications No. 155, Lyon
Protzel C, Ruppin S, Milerski S et al (2009) The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics. Urologe A 48(12):1495–1498
Hughes BE, Leijte JA, Kroon BK et al (2009) Lymph node metastasis in intermediate-risk penile squamous cell cancer: a two-centre experience. Eur Urol 57(4):688–692
Dillner J, Krogh G von, Horenblas S, Meijer CJ (2000) Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (205):189–193
Madsen BS, Brule AJ van den, Jensen HL et al (2008) Risk factors for squamous cell carcinoma of the penis – population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 17:2683–2691
Favorito LA, Nardi AC, Ronalsa M et al (2008) Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 34:587–591
Harish K, Ravi R (1995) The role of tobacco in penile carcinoma. Br J Urol 75:375–377
Rubin MA, Kleter B, Zhou M et al (2001) Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159:1211–1218
Cubilla AL, Dillner J, Schellhammer PF et al (2004) Tumours of the Penis. In: Eble JN Sauter G, Epstein JI, Sesterhenn IA (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, pp 280–290
Sobin LH, Gospodariwicz M, Wittekind C (Hrsg) (2009) TNM Classification of Malignant Tumours. UICC International Union Against Cancer, 7th edn. Wiley-Blackwell, New York
Poetsch M, Schuart BJ, Schwesinger G et al (2007) Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Mod Pathol 20:1069–1077
Poetsch M, Hemmerich M, Kakies C et al (2011) Alterations in the tumor suppressor gene p16(INK4 A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 458:221–229
Martins AC, Faria SM, Cologna AJ et al (2002) Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol 167:89–92
Pizzocaro G, Algaba F, Horenblas S et al (2010) EAU penile cancer guidelines 2009. Eur Urol 57(6):1002–1012
Kayes O, Minhas S, Allen C et al (2007) The role of magnetic resonance imaging in the local staging of penile cancer. Eur Urol 51:1313–1318
Velazquez EF, Barreto JE, Rodriguez I et al (2004) Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol 12:139–146
Protzel C, Alcaraz A, Horenblas S et al (2009) Lymphadenectomy in the surgical management of penile cancer. Eur Urol 55:1075–1088
Kroon BK, Horenblas S, Lont AP et al (2005) Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 173:816–819
Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM (2006) Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int 97:1225–1228
Scher B, Seitz M, Reiser M et al (2005) 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 46:1460–1465
Leijte JA, Kirrander P, Antonini N et al (2008) Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol 54:161–168
Minhas S, Kayes O, Hegarty P et al (2005) What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int 96:1040–1043
Alnajjar HM, Lam W, Bolgeri M et al (2012) Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 62(5):923–928
Schlenker B, Gratzke C, Seitz M et al (2011) Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: long-term follow-up. Urol Oncol 29(6):788–793
Hegarty PK, Shabbir M, Hughes B et al (2009) Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: recommendations from the United Kingdom experience. World J Urol 27:179–187
Crevoisier R de, Slimane K, Sanfilippo N et al (2009) Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys 74:1150–1156
Ficarra V, Galfano A (2007) Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma? Eur Urol 52:17–19
Pizzocaro G, Piva L, Bandieramonte G, Tana S (1997) Up-to-date management of carcinoma of the penis. Eur Urol 32:5–15
Dexeus FH, Logothetis CJ, Sella A et al (1991) Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146:1284–1287
Haas GP, Blumenstein BA, Gagliano RG et al (1999) Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 161:1823–1825
Hakenberg OW, Nippgen JB, Froehner M et al (2006) Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 98:1225–1227
Pizzocaro G, Nicolai N, Milani A (2009) Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 55(3):546–551
Pagliaro LC, Williams DL, Daliani D et al (2010) Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 28:3851–3857
Pizzocaro G, Piva L (1988) Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27:823–824
Necchi A, Nicolai N, Colecchia M et al (2011) Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 29:e650–e652
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seinen Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Protzel, C., Hakenberg, O. Peniskarzinom. Urologe 52, 87–98 (2013). https://doi.org/10.1007/s00120-012-3004-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-012-3004-5